Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
Study Details
Study Description
Brief Summary
Phase 3 study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia (NP) including hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP), complicated urinary tract infections (cUTI), or bloodstream infections (BSI) due to metallo-β-lactamase (MBL)- producing Gram-negative bacteria.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
This is a prospective, randomized, multicenter, open-label, parallel group, comparative study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia (NP) including hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP), complicated urinary tract infections (cUTI), or bloodstream infections (BSI) due to metallo-β-lactamase (MBL)- producing Gram-negative bacteria.
The study will randomize approximately 60 subjects in a 2:1 randomization scheme (ATM-AVI:
BAT) with infections due to MBL-producing Gram-negative bacteria. Molecular testing at the central microbiology laboratory will be performed to confirm the MBL status of the organism upon study completion or at pre-designated intervals.
The study will consist of a Screening Visit (Visit 1), a Baseline visit (Visit 2) on Day 1 of the study treatment, ongoing treatment visits (Visits 3 to 15) from Day 2 to Day 14, an End of Treatment (EOT) visit (Visit 16) within 24 hours after the last infusion, a Test of Cure (TOC) visit (Visit 17) on Day 28 (±3 days) and a Late Follow Up (LFU) visit (Visit 18) on Day 45 (±3 days).
Subjects will be stratified at randomization based on infection type (cIAI, HAP/VAP, cUTI or BSI). The number of subjects with cUTI will be no more than approximately 75% of the study population.
After obtaining written informed consent and confirming eligibility, subjects will be randomized in a 2:1 ratio to the ATM AVI treatment arm or the BAT treatment arm according to a central randomization schedule (approximately 40 (ATM AVI) and approximately 20 (BAT) subjects per group).
The duration of treatment is 5 to 14 days for cIAI, cUTI and BSI and 7 to 14 days for HAP/VAP. Each subject is expected to complete the study, including the LFU visit. The precise duration of treatment will be determined by the investigator based on the subject's severity of infection and subsequent response to treatment.
For subjects randomized to ATM AVI treatment arm, sparse blood samples will be collected for population pharmacokinetic (PK) assessments and PK/pharmacodynamic (PD) relationships will be evaluated in subjects where plasma samples and microbiological response data have been collected.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: ATM- AVI Aztreonam- Avibactam (ATM-AVI) Active Treatment Arm
|
Combination Product: ATM-AVI
ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.
Other Names:
|
| Active Comparator: Best Available Therapy (BAT) Comparator Treatment Arm
|
Drug: BAT
The comparator treatments in this study are to be the best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT for each subject must be recorded prior to randomization. Acceptable BAT may include but not limit to the following Aminoglycoside; Colistin (or polymixin B if colistin not available/accessible); Fosfomycin; Meropenem; Tigecycline. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Proportion of subjects with clinical cure in the microbiological Intent-To-Treat (micro-ITT) analysis set [Up to 31 days]
Proportion of subjects with clinical cure at the TOC visit in the micro-ITT analysis set
Secondary Outcome Measures
- Proportion of subjects with clinical cure in the Microbiologically Evaluable (ME) analysis set [up to 31 days]
Proportion of subjects with clinical cure at the TOC visit in the ME analysis set
- Proportion of subjects with clinical cure in the micro-ITT and ME analysis sets [within 24 hours after the completion of the last infusion of IV study treatment]
Proportion of subjects with clinical cure at the EOT visit in the micro-ITT and ME analysis sets
- Proportion of subjects with a favorable per subject microbiological response in the micro ITT and ME analysis sets [within 24 hours after the completion of the last infusion of IV study treatment and up to 31 days]
Proportion of subjects with a favorable (defined as eradication or presumed eradication) per subject microbiological response at the EOT and TOC visits in the micro-ITT and ME analysis sets
- Proportion of subjects with a favorable per pathogen microbiological response in the micro ITT and ME analysis sets [within 24 hours after the completion of the last infusion of IV study treatment and up to 31 days]
Proportion of subjects with a favorable per pathogen microbiological response at the EOT and TOC visits in the micro- ITT and ME analysis sets
- Proportion of subjects who died on or before 28 days in the Intent-To-Treat (ITT) and micro-ITT analysis sets [from randomization up to 31 days]
Proportion of subjects who died on or before 28 days from randomization in ITT and micro-ITT analysis sets
- Incidence and severity of adverse events [from first dose up to 48 days]
Safety and tolerability as assessed by adverse events
- Incidence of abnormalities in physical examination [from first dose up to 48 days]
Safety and tolerability as assessed by physical examination
- Incidence of vital sign abnormalities [from first dose up to 48 days]
Safety and tolerability as assessed by vital sign assessments
- Incidence of ECG abnormalities [from first dose up to 48 days]
Safety and tolerability as assessed by ECGs assessments
- Incidence of clinical laboratory abnormalities [from first dose up to 48 days]
Safety and tolerability as assessed by clinical laboratory assessments
Eligibility Criteria
Criteria
Inclusion Criteria All Subjects
-
Subject must be ≥18 years of age.
-
Evidence of a personally signed and dated informed consent document indicating that the subject or a legally acceptable representative has been informed of all pertinent aspects of the study.
-
Subjects must have a confirmed diagnosis of serious bacterial infection, specifically cIAI, HAP/VAP, cUTI, or BSI requiring administration of IV antibacterial therapy.
-
Subjects must have an MBL- positive Gram- negative bacteria (an Enterobacteriaceae and/or Stenotrophomonas maltophilia for which the imipenem or meropenem MIC is ≥ 4 µg/mL), that was isolated from an appropriate specimen obtained within 5 days prior to screening.
-
Female subject of childbearing potential must have a negative serum or urine pregnancy test, with sensitivity of at least 25 mIU/mL.
-
Subjects who have received appropriate prior systemic antibiotic[s] for a carbapenem non-susceptible pathogen must meet the following criteria (Note: antibiotic[s] is considered appropriate if microbiological susceptibility test results show that all carbapenem non-susceptible pathogens are susceptible to the systemic antibiotic[s] received):
-
Worsening or lack of improvement of objective symptoms or signs of infection after at least 48 hours of antibacterial therapy Note: Symptomatic subjects (see inclusion criteria 3 and 4) with an isolated causative pathogen that was not susceptible to the prior systemic therapy are eligible for this trial.
-
Subject must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Additional Inclusion Criteria- cIAI Subjects
-
Subject must have a specimen obtained from an abdominal source during a surgical intervention within 5 days prior to screening from which a study qualifying pathogen was isolated upon culture. Surgical intervention includes open laparotomy, percutaneous drainage of an abscess, or laparoscopic surgery.
-
The subject has at least 1 of the following diagnosed during the surgical intervention:
-
Cholecystitis with gangrenous rupture or perforation or progression of the infection beyond the gallbladder wall;
-
Diverticular disease with perforation or abscess;
-
Appendiceal perforation or peri-appendiceal abscess;
-
Acute gastric or duodenal perforations, only if operated on >24 hours after diagnosis;
-
Traumatic perforation of the intestines, only if operated on >12 hours after diagnosis;
-
Other secondary peritonitis (not primary/ spontaneous bacterial peritonitis associated with cirrhosis or chronic ascites);
-
Intra abdominal abscess (including of the liver and spleen provided that there is extension beyond the organ with evidence of intra peritoneal involvement).
- Subject has at least 1 of the following signs / symptoms from each of the following 2 groups:
-
Group A: Evidence of systemic inflammatory response:
-
Documented fever (defined as body temperature ≥38°C) or hypothermia (with a rectal core body temperature ≤35°C);
-
Elevated white blood cells (WBC) (>12000 cells/µL);
-
Systolic blood pressure (SBP) <90 mmHg or mean arterial pressure (MAP) <70 mmHg, or a SBP decrease of >40 mmHg;
-
Increased heart rate ( >90 beats per minute [bpm]) and respiratory rate (>20 breaths/min);
-
Hypoxemia (defined as oxygen [O2] saturation <95% by pulse oximetry);
-
Altered mental status.
-
Group B: Physical findings consistent with intra abdominal infection, such as:
-
Abdominal pain and/or tenderness, with or without rebound;
-
Localized or diffuse abdominal wall rigidity;
-
Abdominal mass.
Additional Inclusion Criteria - HAP/VAP Subjects
-
Onset of symptoms >48 hours after admission or <7 days after discharge from an inpatient care facility (for which the duration of admission was >3 days).
-
New or worsening infiltrate on chest X- ray (or computerized tomography [CT]- scan) obtained within 48 hours prior to randomization.
-
At least 1 of the following:
• Documented fever (temperature ≥38°C) or hypothermia (rectal/core temperature ≤35°C);
• WBC ≥10,000 cells/mm3, leukopenia with total WBC ≤4500 cells/mm3, or >15% immature neutrophils (bands) noted on peripheral blood smear.
- At least 2 of the following:
• A new cough (or worsening of cough at Baseline);
• Production of purulent sputum or purulent endotracheal secretions;
• Auscultatory finding consistent with pneumonia/pulmonary consolidation (eg, rales, rhonchi, bronchial breath sounds, dullness on percussion, egophony);
• Dyspnea, tachypnea, or hypoxemia (O2 saturation <90% or partial pressure of O2 [pO2]<60 mmHg while breathing room air);
• Need for acute changes in the ventilator support status/system to enhance oxygenation, as determined by worsening oxygenation (arterial blood gas [ABG] or pO2 in arterial blood [PaO2]/fraction of inspired O2 [FiO2]) or needed changes in the amount of positive end expiratory pressure.
- Subjects must have a respiratory specimen obtained within 5 days prior to screening for Gram stain and culture from which a study qualifying pathogen was isolated upon culture. This includes culture of either an expectorated sputum or a specimen of respiratory secretions obtained by endotracheal aspiration in intubated subjects, or by bronchoscopy with bronchoalveolar lavage (BAL), mini BAL or protected specimen brush (PSB) sampling.
Additional Inclusion Criteria - cUTI Subjects
-
Subject had urine within 5 days prior to screening that cultured positive; containing ≥10^5 colony forming unit (CFU)/mL of at least 1 carbapenem non susceptible, MBL positive Gram negative bacteria, ie, the isolate from the study qualifying culture.
-
Subject had pyuria in the 5 days prior to screening as determined by a midstream clean catch or catheterized urine specimen with ≥10 white blood cells (WBCs) per HighPower Field (HPF) on standard examination of urine sediment or ≥10 WBCs/mm3 in unspun urine.
-
Subject demonstrates either acute pyelonephritis or complicated lower UTI without pyelonephritis as defined by the following criteria:
- Acute pyelonephritis indicated by flank pain (which must have onset or worsened within 7 days of enrollment) or costovertebral angle tenderness on examination and at least 1 of the following: i) Fever, defined as body temperature ≥38°C (with or without patient symptoms of rigor, chills, or warmth); ii) Nausea and/or vomiting. OR b. Complicated lower UTI, as indicated by qualifying symptoms plus at least 1 complicating factor as follows: i) Qualifying symptoms: subject must have at least 2 of the following symptoms with at least 1 symptom from Group A:
• Group A symptoms include dysuria, urgency, frequency, and or suprapubic pain;
- Group B symptoms include fever (defined as body temperature ≥38°C with or without patient symptoms of rigor, chills, warmth), nausea, and/or vomiting.
- Complicating factors: subject must have at least 1 of the following complicating factors:
• Documented history of urinary retention (male subjects);
• Obstructive uropathy that is scheduled to be medically or surgically relieved during study therapy and before the EOT;
-
Functional or anatomical abnormality of the urogenital tract, including anatomic malformations or neurogenic bladder, or with a postvoid residual urine volume of at least 100 mL;
-
Use of intermittent bladder catheterization or presence of an indwelling bladder catheter for at least 48 hours;
-
Urogenital procedure (such as cystoscopy or urogenital surgery) within the 7 days prior to obtainment of the specimen used for the study qualifying culture.
Additional Inclusion Criteria - BSI Subjects
-
Subject has a confirmed diagnosis of primary BSI or catheter related BSI (CR- BSI).
-
Consecutive positive duplicate blood cultures (n=2) within 5 days prior to screening indicating presence of a carbapenem non- susceptible, MBL-producing Gram- negative bacteria. Subjects with polymicrobial blood infections may be included in the study.
-
Signs and symptoms of systemic infection characterised by at least one of the following:
- Chills, rigors, or fever (temperature of ≥38.0°C or ≥100.4°F); b. Elevated white blood cell count (≥10,000/mm3) or left shift (>15% immature polymorphonuclear leukocytes (PMNs)).
Exclusion Criteria All Subjects 1. Subject has an Acute Physiology and Chronic Health Evaluation (APACHE) II score >30.
-
Subjects unlikely to respond to up to 14 days of study treatment. 3. History of serious allergic reaction (anaphylaxis, angioedema, bronchospasm, hypersensitivity) to any systemic antibacterial allowed per protocol.
-
Subject has previously been treated with ATM-AVI Subject with known Clostridium difficile associated diarrhea. 5. Subjects with perinephric infection. 6. Colonization with an MBL-producing Gram-negative bacteria without signs or symptoms.
-
Estimated CrCL ≤15 mL/min or anticipated requirement for dialysis during the study.
-
Hepatic disease as indicated by ALT or AST >3 x ULN at Screening. Exception: AST and/or ALT up to 5 x ULN if these elevations are acute and directly related to the infectious process.
-
Bilirubin >2 x ULN, unless related to the acute infection or due to known Gilbert's disease.
-
Alkaline phosphatase (ALP) >3 x ULN. Exception: up to <5 x ULN if this value is acute and related to the infectious process.
-
Absolute neutrophil count <500/mm3.
Additional Exclusion Criteria - cIAI Subjects
-
Subject has infections limited to the hollow viscous, such as simple cholecystitis, gangrenous cholecystitis without rupture, and simple appendicitis, or has acute suppurative cholangitis, infected necrotizing pancreatitis, or pancreatic abscess.
-
Subject has abdominal wall abscess or small bowel obstruction without perforation or ischemic bowel without perforation.
-
Subject has a cIAI managed by staged abdominal repair (STAR), or "open abdomen" technique, or marsupialization. This criterion is intended to exclude subjects in whom the abdomen is left open, particularly those for whom re operation is planned.
-
Subject who has prior liver, pancreas or small bowel transplant.
Additional Exclusion Criteria - HAP/VAP Subjects 1. APACHE II score <10. 2. Subjects with lung abscess, pleural empyema, or post obstructive pneumonia. 3. Subject is a recipient of a lung or heart transplant. 4. Subjects with myasthenia gravis.
Additional exclusion criteria - cUTI Subjects
-
Subjects with suspected or confirmed complete obstruction of any portion of the urinary tract, perinephric or intrarenal abscess, or prostatitis, or history of any illness that, in the opinion of the investigator, may confound the results of the study or pose additional risk in administering the study therapy to the subject.
-
Subjects with renal transplantation.
-
Subjects with a permanent urinary diversion (eg, with ileal loops, cutaneous ureterostomy or vesicoureteral reflux).
-
Subjects who are likely to receive ongoing antibacterial drug prophylaxis after treatment of cUTI (eg, subjects with vesico-ureteric reflux).
-
Any recent history of trauma to the pelvis or urinary tract.
-
Subjects with uncomplicated urinary tract infections (generally female subjects with urinary frequency, urgency, or pain or discomfort without systemic symptoms or signs of infection).
Additional exclusion criteria - BSI Subjects
- Subject has a prosthetic cardiac valve or synthetic endovascular graft. 2. Subject has a suspected or documented medical condition with well-defined requirement for prolonged antibiotic treatment (eg, infectious endocarditis, osteomyelitis/septic arthritis, undrainable/undrained abscess, unremoveable/unremoved prosthetic associated infection).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Banner University Medical Center Tucson | Tucson | Arizona | United States | 85719 |
| 2 | Harbor-UCLA Medical Center | Torrance | California | United States | 90502 |
| 3 | Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center | Torrance | California | United States | 90502 |
| 4 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Torrance | California | United States | 90502 |
| 5 | Harbor-UCLA Medical Center | Torrance | California | United States | 90509 |
| 6 | Hospital San Roque | Cordoba | Argentina | 5000 | |
| 7 | The First Affiliated Hospital of Shantou University Medical College | Shantou | Guangdong | China | 515041 |
| 8 | Hunan Province People's Hospital | Changsha | Hunan | China | 410005 |
| 9 | Huashan Hospital Fudan University | Shanghai | Shanghai | China | 200040 |
| 10 | The First Hospital of Kunming | Kunming | Yunnan | China | 650034 |
| 11 | The First Hospital of Kunming | Kunming | China | ||
| 12 | General Hospital of Athens "Evangelismos" | Athens | Greece | 10676 | |
| 13 | General and Chest Diseases Hospital "Sotiria" | Athens | Greece | 11527 | |
| 14 | General Hospital of Athens "Laiko", | Athens | Greece | 11527 | |
| 15 | University General Hospital "ATTIKON", Medicine and Infectious Diseases | Athens | Greece | 12462 | |
| 16 | University General Hospital of Heraklion | Heraklion, Crete | Greece | 71110 | |
| 17 | University General Hospital of Larissa | Larissa | Greece | 41110 | |
| 18 | Artemis hospital | Gurugram | Haryana | India | 122001 |
| 19 | Government medical College | Kozhikode | Kerala | India | 673008 |
| 20 | Deenanath Mangeshkar Hospital And Research Centre | Pune | Maharashtra | India | 411004 |
| 21 | S.R.Kalla Memorial Gastro & General Hospital | Jaipur | Rajasthan | India | 302001 |
| 22 | Apollo Hospitals Enterprise Limited | Chennai | Tamil NADU | India | 600006 |
| 23 | Victoria Hospital, Bangalore Medical College and Research Institute | Bangalore | India | 560002 | |
| 24 | Hospital Kuala Lumpur | Kuala Lumpur | Wilayah Persekutuan Kuala Lumpur | Malaysia | 50586 |
| 25 | University Malaya Medical Centre | Kuala Lumpur | Malaysia | 59100 | |
| 26 | Hospital Civil de Guadalajara "Fray Antonio Alcalde" | Guadalajara | Jalisco | Mexico | 44280 |
| 27 | Davao Doctors Hospital | Davao City | Philippines | 8000 | |
| 28 | Makati Medical Center | Makati City | Philippines | 1229 | |
| 29 | Manila Doctors Hospital | Manila | Philippines | 1000 | |
| 30 | St. Luke's Medical Center | Quezon City | Philippines | 1112 | |
| 31 | Institutul National de Boli Infectioase "Prof. Dr. Matei Bals" | Bucuresti | Romania | 021105 | |
| 32 | Spitalul Clinic de Boli Infectioase si Tropicale "Dr. Victor Babes" | Bucuresti | Romania | 030303 | |
| 33 | Spitalul Clinic de Boli Infectioase Cluj Napoca | Cluj-Napoca | Romania | 400348 | |
| 34 | Spitalul Clinic de Boli Infectioase "Sf. Parascheva" Iasi | Iasi | Romania | 700116 | |
| 35 | Spitalul Clinic Judetean de Urgenta "Pius Brinzeu" | Timisoara | Romania | 300723 | |
| 36 | State Budgetary Healthcare Institution "Regional Clinical Hospital No. 2" of the Ministry of Health | Krasnodar | Russian Federation | 350012 | |
| 37 | SBHI of the city of Moscow "N.I.Pirogov City Clinical Hospital # 1" | Moscow | Russian Federation | 119049 | |
| 38 | GBUZ of Novosibirsk region "City clinical hospital #2" | Novosibirsk | Russian Federation | 630051 | |
| 39 | OGBUZ "Smolensk Regional Clinical Hospital" | Smolensk | Russian Federation | 214018 | |
| 40 | FSBEI of HE "Smolensk State Medical University" of the Ministry of Health of the RF | Smolensk | Russian Federation | 214019 | |
| 41 | SRI of Antimicrobial Chemotherapy | Smolensk | Russian Federation | 214019 | |
| 42 | Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City | Taiwan | 807 | |
| 43 | Kaohsiung Veterans General Hospital | Kaohsiung | Taiwan | 81362 | |
| 44 | National Taiwan University Hospital | Taipei City | Taiwan | 10002 | |
| 45 | Faculty of Medicine Siriraj Hospital | Bangkoknoi | Bangkok | Thailand | 10700 |
| 46 | Srinagarind Hospital, Division of lnfectious Disease and Tropical Medicine | Muang | Khonkaen | Thailand | 40002 |
| 47 | Bamrasnaradura Infectious Disease Institute (BIDI) | Muang | Nonthaburi | Thailand | 11000 |
| 48 | Songklanagarind Hospital, Prince of Songkla University | Hat Yai | Songkhla | Thailand | 90110 |
Sponsors and Collaborators
- Pfizer
- Allergan
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- C3601009
- 2017-004544-38
- ASSEMBLE